Celsion Corporation Highlights Progress in its DNA-based Vaccine Program PLACCINE DNA-based Vaccine Demonstrates Robust Response in Murine Model LAWRENCEVILLE, N.J., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage company...

Celsion Corporation Highlighted its PLACCINE Vaccine Platform Technology During Oral Presentation at the World Vaccine Congress Proprietary, Formulated DNA Plasmid Vaccine Candidate Shows Neutralizing Activity Against 2 Strains of the COVID-19 Virus The Goal to Provide Broader Range Protection within a Highly Flexible...